BMS encourages cancer patients to look 'Beyond Chemotherapy' in new unbranded campaign

Cancer Care
The common dread around chemotherapy is behind Bristol Myers Squibb's new lung cancer awareness effort. (iStock/Getty images)

A cancer diagnosis is never easy, and one of the most common patient fears is chemotherapy. Bristol Myers Squibb’s new “Beyond Chemotherapy” awareness effort looks to assure lung cancer patients that there may be another way to manage the disease. 

A 30-second TV spot features various people looking out of windows while a voice-over says, “A lung cancer diagnosis can leave you holding your breath.” Patients breathe on a window, fogging it up, and write various cancer-treatment related questions into the condensation, including: “Will I need chemo?”

BMS’ answers come written the same way on windows, with the final promise, “We’re looking beyond chemo.”

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

RELATED: BMS rolls cancer survivor campaign with TV actor spokesman and a new mission

While the spot, which first aired in May, is unbranded, BMS’ blockbuster immuno-oncology drug Opdivo is now approved as part of a chemo-free regimen for some previously untreated lung cancer patients.

In May, Opdivo got its first non-small cell lung cancer first-line approval in combination with fellow BMS checkpoint inhibitor Yervoy for patients whose tumors test positive for biomarker PD-L1. Just a few weeks later, BMS received another first-line nod for the two drugs, this time given alongside two cycles of platinum chemo.

Both the non-chemo and chemo options for the BMS drug pair, however, still face stiff competition from archrival Merck & Co.’s Keytruda. Keytruda has been grabbing first-line market share for three years on the back of data showing it could cut patients’ death risk by 51% when combined with chemo.

A first-ever branded Opdivo-plus-Yervoy branded TV commercial began last week and includes the message that the tandem is the "first and only approved chemo-free combination of two immunotherapies." The TV ad recalls the earliest Opdivo work, reviving the phrase, "a chance to live longer," first used in Opdivo's 2015 debut commercial.

The new BMS TV ad taps into the appeal of the possibility to treat cancer without chemotherapy, typically a grueling process with lasting effects.

The final visual in the ad is the word “hope” written into the condensation, followed by a call to visit the campaign website for more information.

RELATED: Bristol Myers Squibb takes on racial inequality with $300M pledge to up diversity, improve healthcare access

While BMS hadn’t focused on the chemotherapy message previously, it has run awareness campaigns across a range of cancer topics since 2015, when it started driving recognition for immuno-oncology. It most recently enlisted popular “This is Us” actor Sterling K. Brown for the campaign “Survivorship Today” to raise awareness of the struggles cancer survivors may face post-treatment. 

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.